Literature DB >> 25987214

The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells.

Kanae Bekki1, Helena Vogel1, Wen Li1, Tomohiro Ito1, Colleen Sweeney2, Thomas Haarmann-Stemmann3, Fumio Matsumura4, Christoph F A Vogel5.   

Abstract

The aryl hydrocarbon receptor (AhR) is well known as a ligand binding transcription factor regulating various biological effects. Previously we have shown that long-term exposure to estrogen in breast cancer cells caused not only down regulation of estrogen receptor (ER) but also overexpression of AhR. The AhR interacts with several cell signaling pathways associated with induction of tyrosine kinases, cytokines and growth factors which may support the survival roles of AhR escaping from apoptosis elicited by a variety of apoptosis inducing agents in breast cancer. In this study, we studied the anti-apoptotic role of AhR in different breast cancer cells when apoptosis was induced by exposure to UV light and chemotherapeutic agents. Activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in AhR overexpressing breast cancer cells effectively suppressed the apoptotic response induced by UV-irradiation, doxorubicin, lapatinib and paclitaxel. The anti-apoptotic response of TCDD was uniformly antagonized by the treatment with 3'methoxy-4'nitroflavone (MNF), a specific antagonist of AhR. TCDD's survival action of apoptosis was accompanied with the induction of well-known inflammatory genes, such as cyclooxygenase-2 (COX-2) and NF-κB subunit RelB. Moreover, TCDD increased the activity of the immunosuppressive enzyme indoleamine 2, 3-dioxygenase (IDO), which metabolizes tryptophan to kynurenine (Kyn) and mediates tumor immunity. Kyn also acts as an AhR ligand like TCDD, and kyn induced an anti-apoptotic response in breast cancer cells. Accordingly, our present study suggests that AhR plays a pivotal role in the development of breast cancer via the suppression of apoptosis, and provides an idea that the use of AhR antagonists with chemotherapeutic agents may effectively synergize the elimination of breast cancer cells.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AhR; Apoptosis; Breast cancer; IDO; NF-κB; TCDD

Mesh:

Substances:

Year:  2014        PMID: 25987214      PMCID: PMC4438266          DOI: 10.1016/j.pestbp.2014.12.021

Source DB:  PubMed          Journal:  Pestic Biochem Physiol        ISSN: 0048-3575            Impact factor:   3.963


  42 in total

1.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

2.  Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells.

Authors:  Regine Lüpertz; Wim Wätjen; Regine Kahl; Yvonni Chovolou
Journal:  Toxicology       Date:  2010-03-25       Impact factor: 4.221

Review 3.  Endogenous kynurenines as targets for drug discovery and development.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Nat Rev Drug Discov       Date:  2002-08       Impact factor: 84.694

4.  Taxol induced apoptosis regulates amino acid transport in breast cancer cells.

Authors:  Yanyuan Wu; Dejun Shen; Zujian Chen; Sheila Clayton; Jaydutt V Vadgama
Journal:  Apoptosis       Date:  2006-12-29       Impact factor: 4.677

5.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits growth factor withdrawal-induced apoptosis in the human mammary epithelial cell line, MCF-10A.

Authors:  J W Davis; K Melendez; V M Salas; F T Lauer; S W Burchiel
Journal:  Carcinogenesis       Date:  2000-05       Impact factor: 4.944

Review 6.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  RelB, a new partner of aryl hydrocarbon receptor-mediated transcription.

Authors:  Christoph F A Vogel; Eric Sciullo; Wen Li; Pat Wong; Gwendal Lazennec; Fumio Matsumura
Journal:  Mol Endocrinol       Date:  2007-09-06

Review 8.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens: characterization and mechanism of action.

Authors:  S Safe; B Astroff; M Harris; T Zacharewski; R Dickerson; M Romkes; L Biegel
Journal:  Pharmacol Toxicol       Date:  1991-12

9.  TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents.

Authors:  Gerd Pääjärvi; Matti Viluksela; Raimo Pohjanvirta; Ulla Stenius; Johan Högberg
Journal:  Carcinogenesis       Date:  2004-09-30       Impact factor: 4.944

10.  Targeting COX-2 abrogates mammary tumorigenesis: Breaking cancer-associated suppression of immunosurveillance.

Authors:  Nune Markosyan; Edward P Chen; Emer M Smyth
Journal:  Oncoimmunology       Date:  2014-06-30       Impact factor: 8.110

View more
  25 in total

Review 1.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 2.  State of the evidence 2017: an update on the connection between breast cancer and the environment.

Authors:  Janet M Gray; Sharima Rasanayagam; Connie Engel; Jeanne Rizzo
Journal:  Environ Health       Date:  2017-09-02       Impact factor: 5.984

3.  Maternal Resveratrol Treatment Reduces the Risk of Mammary Carcinogenesis in Female Offspring Prenatally Exposure to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin.

Authors:  Tássia C de Lima E Silva; Livia T R da Silveira; Mariana F Fragoso; Flávia R M da Silva; Meire F Martinez; Joyce R Zapaterini; Odair H G Diniz; Wellerson R Scarano; Luis F Barbisan
Journal:  Horm Cancer       Date:  2017-08-07       Impact factor: 3.869

4.  Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.

Authors:  Ayse Basak Engin; Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Aryl Hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Human Ovarian Cancer via Activation of PI3K/Akt, β-Catenin, and Epithelial to Mesenchymal Transition Pathways.

Authors:  Lubna Therachiyil; Roopesh Krishnankutty; Fareed Ahmad; Jericha M Mateo; Shahab Uddin; Hesham M Korashy
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

Review 6.  Role of AhR in positive regulation of cell proliferation and survival.

Authors:  Jiuheng Yin; Baifa Sheng; Yuan Qiu; Kunqiu Yang; Weidong Xiao; Hua Yang
Journal:  Cell Prolif       Date:  2016-08-14       Impact factor: 6.831

Review 7.  Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

Authors:  Mariana Segovia-Mendoza; María E González-González; David Barrera; Lorenza Díaz; Rocío García-Becerra
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

8.  Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer.

Authors:  Maria Letícia Baptista Salvadori; Pedro Kastein Faria da Cunha Bianchi; Luiz Henrique Gebrim; Renata Santos Silva; José Roberto Kfoury
Journal:  Med Oncol       Date:  2015-10-06       Impact factor: 3.064

9.  The aryl hydrocarbon receptor repressor - More than a simple feedback inhibitor of AhR signaling: Clues for its role in inflammation and cancer.

Authors:  Christoph F A Vogel; Thomas Haarmann-Stemmann
Journal:  Curr Opin Toxicol       Date:  2017-03-01

Review 10.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.